Cargando…

Discovery of a novel AR/HDAC6 dual inhibitor for prostate cancer treatment

Androgen receptor (AR) and histone deacetylase 6 (HDAC6) are important targets for cancer therapy. Given that both AR antagonists and HDAC6 inhibitors modulate AR signaling, a novel AR/HDAC6 dual inhibitor is investigated for its anticancer effects in castration-resistant prostate cancer (CRPC). Zet...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Maojun, Zheng, Hao, Li, Yubin, Huang, Huichao, Min, Xiaoli, Dai, Shuyan, Zhou, Wenqiang, Chen, Zhuchu, Xu, Guangyu, Chen, Yongheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals 2021
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7993727/ https://www.ncbi.nlm.nih.gov/pubmed/33621955 http://dx.doi.org/10.18632/aging.202554

Ejemplares similares

Fibroblast Growth Factor Receptors (FGFRs): Structures and Small Molecule Inhibitors
por: Dai, Shuyan, et al.
Publicado: (2019)

The Radiosensitization of Sodium Glycididazole on Nasopharyngeal Carcinoma Cells via Enhancing DNA Damage and Promoting Apoptosis
por: Min, Xiaoli, et al.
Publicado: (2019)

Structural insights into the potency and selectivity of covalent pan-FGFR inhibitors
por: Qu, Lingzhi, et al.
Publicado: (2022)

Dual inhibition of AKT‐mTOR and AR signaling by targeting HDAC3 in PTEN‐ or SPOP‐mutated prostate cancer
por: Yan, Yuqian, et al.
Publicado: (2018)

Acetylation-mediated degradation of HSD17B4 regulates the progression of prostate cancer
por: Huang, Huichao, et al.
Publicado: (2020)

Discovery of BRAF/HDAC Dual Inhibitors Suppressing Proliferation of Human Colorectal Cancer Cells
por: Li, Yingjun, et al.
Publicado: (2022)

Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosis
por: Murahari, Sridhar, et al.
Publicado: (2017)

Novel Single Inhibitor of HDAC6/8 and Dual Inhibitor of PI3K/HDAC6 as Potential Alternative Treatments for Prostate Cancer
por: Guerra, Fabiana Sélos, et al.
Publicado: (2021)

Discovery and biological evaluation of novel CARM1/HDAC2 dual-targeting inhibitors with anti-prostate cancer agents
por: Liang, Sudong, et al.
Publicado: (2023)

Structure-based design of a dual-warhead covalent inhibitor of FGFR4
por: Chen, Xiaojuan, et al.
Publicado: (2022)

Dissection of Anti-tumor Activity of Histone Deacetylase Inhibitor SAHA in Nasopharyngeal Carcinoma Cells via Quantitative Phosphoproteomics
por: Huang, Huichao, et al.
Publicado: (2020)

Author Correction: Structure-based design of a dual-warhead covalent inhibitor of FGFR4
por: Chen, Xiaojuan, et al.
Publicado: (2022)

Suberoylanilide Hydroxamic Acid (SAHA) Treatment Reveals Crosstalk Among Proteome, Phosphoproteome, and Acetylome in Nasopharyngeal Carcinoma Cells
por: Huang, Huichao, et al.
Publicado: (2022)

CUDC‐907, a novel dual PI3K and HDAC inhibitor, in prostate cancer: Antitumour activity and molecular mechanism of action
por: Hu, Cheng, et al.
Publicado: (2020)

Structural basis of the farnesoid X receptor/retinoid X receptor heterodimer on inverted repeat DNA
por: Jiang, Longying, et al.
Publicado: (2023)

Discovery of spirooxindole-derived small-molecule compounds as novel HDAC/MDM2 dual inhibitors and investigation of their anticancer activity
por: Zhao, Qian, et al.
Publicado: (2022)

S-Adenosylmethionine Affects Cell Cycle Pathways and Suppresses Proliferation in Liver Cells
por: Yan, Lu, et al.
Publicado: (2019)

Afatinib Reverses EMT via Inhibiting CD44-Stat3 Axis to Promote Radiosensitivity in Nasopharyngeal Carcinoma
por: Huang, Huichao, et al.
Publicado: (2022)

The Significance of Serum S100A9 and TNC Levels as Biomarkers in Colorectal Cancer
por: Zhou, Minze, et al.
Publicado: (2019)

Single Inhibitors versus Dual Inhibitors: Role of HDAC in Cancer
por: Roy, Rubi, et al.
Publicado: (2023)

Novel dual LSD1/HDAC6 inhibitor for the treatment of cancer
por: Gajendran, Chandru, et al.
Publicado: (2023)

HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide
por: Canella, Alessandro, et al.
Publicado: (2015)

Corrigendum: Discovery of spirooxindole-derived small-molecule compounds as novel HDAC/MDM2 dual inhibitors and investigation of their anticancer activity
por: Zhao, Qian, et al.
Publicado: (2023)

Mechanism of forkhead transcription factors binding to a novel palindromic DNA site
por: Li, Jun, et al.
Publicado: (2021)

AR-42 induces apoptosis in human hepatocellular carcinoma cells via HDAC5 inhibition
por: Zhang, Mingming, et al.
Publicado: (2016)

Structural basis for DNA recognition by FOXC2
por: Chen, Xiaojuan, et al.
Publicado: (2019)

Discovery of New Uracil and Thiouracil Derivatives as Potential HDAC Inhibitors
por: Elbatrawy, Omnia R., et al.
Publicado: (2023)

AR-42: A Pan-HDAC Inhibitor with Antitumor and Antiangiogenic Activities in Esophageal Squamous Cell Carcinoma
por: Zhu, Yuxuan, et al.
Publicado: (2019)

Correction: HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide
por: Canella, Alessandro, et al.
Publicado: (2023)

Dual-Mode HDAC Prodrug for Covalent Modification and Subsequent Inhibitor Release
por: Daniel, Kevin B., et al.
Publicado: (2015)

Repressing HIF-1α-induced HDAC9 contributes to the synergistic effect of venetoclax and MENIN inhibitor in KMT2Ar AML
por: Ling, Qing, et al.
Publicado: (2023)

Natural chalcones as dual inhibitors of HDACs and NF-κB
por: ORLIKOVA, B., et al.
Publicado: (2012)

Hydroxamic Acids Immobilized on Resins (HAIRs): Synthesis of Dual‐Targeting HDAC Inhibitors and HDAC Degraders (PROTACs)
por: Sinatra, Laura, et al.
Publicado: (2020)

The Design and Synthesis of a New Class of RTK/HDAC Dual-Targeted Inhibitors
por: Zhang, Xuan, et al.
Publicado: (2013)

The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo
por: Booth, Laurence, et al.
Publicado: (2017)

Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs)
por: Luo, Yuxiang, et al.
Publicado: (2020)

Structures of p53/BCL-2 complex suggest a mechanism for p53 to antagonize BCL-2 activity
por: Wei, Hudie, et al.
Publicado: (2023)

Hybrid topoisomerase I and HDAC inhibitors as dual action anticancer agents
por: Cincinelli, Raffaella, et al.
Publicado: (2018)

Quinazoline Based HDAC Dual Inhibitors as Potential Anti-Cancer Agents
por: Dhuguru, Jyothi, et al.
Publicado: (2022)

HDAC inhibitor confers radiosensitivity to prostate stem-like cells
por: Frame, F M, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_9f1cpcfl7a79kji6edfuo3u5tm